TY - JOUR
T1 - Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon
AU - Allencherril, Joseph
AU - Jneid, Hani
AU - Atar, Dan
AU - Alam, Mahboob
AU - Levine, Glenn
AU - Kloner, Robert A.
AU - Birnbaum, Yochai
N1 - Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Successful reperfusion of an infarct-related coronary artery by primary percutaneous intervention or fibrinolysis during acute ST-elevation myocardial infarction (STEMI) does not always restore myocardial tissue perfusion, a phenomenon termed “no-reflow.” Herein we discuss the pathophysiology of this highly prevalent phenomenon and highlight the most salient aspects of its clinical diagnosis and management as well as the limitations of presently used methods. There is a great need for understanding the dynamic nature of no-reflow, as its occurrence is associated with poor cardiovascular outcomes. The no-reflow phenomenon may lend an explanation to the lack of further improvements in in-hospital mortality in STEMI patients despite decreases in door-to-balloon time. Hence, no-reflow potentially presents an important target for investigators interested in improving outcomes in STEMI.
AB - Successful reperfusion of an infarct-related coronary artery by primary percutaneous intervention or fibrinolysis during acute ST-elevation myocardial infarction (STEMI) does not always restore myocardial tissue perfusion, a phenomenon termed “no-reflow.” Herein we discuss the pathophysiology of this highly prevalent phenomenon and highlight the most salient aspects of its clinical diagnosis and management as well as the limitations of presently used methods. There is a great need for understanding the dynamic nature of no-reflow, as its occurrence is associated with poor cardiovascular outcomes. The no-reflow phenomenon may lend an explanation to the lack of further improvements in in-hospital mortality in STEMI patients despite decreases in door-to-balloon time. Hence, no-reflow potentially presents an important target for investigators interested in improving outcomes in STEMI.
KW - Cardiovascular disease
KW - Ischemic heart disease
KW - Microvascular disease
KW - Myocardial infarction
UR - http://www.scopus.com/inward/record.url?scp=85071025654&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071025654&partnerID=8YFLogxK
U2 - 10.1007/s10557-019-06901-0
DO - 10.1007/s10557-019-06901-0
M3 - Review article
C2 - 31418141
AN - SCOPUS:85071025654
SN - 0920-3206
VL - 33
SP - 589
EP - 597
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
IS - 5
ER -